{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:51:09Z","timestamp":1763754669826,"version":"3.45.0"},"reference-count":21,"publisher":"Oncology Nursing Society (ONS)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2025,3,14]]},"DOI":"10.1188\/25.cjon.119-124","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T15:11:06Z","timestamp":1742224266000},"page":"119-124","source":"Crossref","is-referenced-by-count":0,"title":["Buprenorphine: Applications in Oncology and Palliative Care"],"prefix":"10.1188","volume":"29","author":[{"given":"Shila","family":"Pandey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Viola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Aapro, M., Fogli, S., Morlion, B., & Danesi, R. (2024). Opioid metabolism and drug\u2013drug interaction in cancer. Oncologist, 29(11), 931\u2013942. https:\/\/doi.org\/10.1093\/oncolo\/oyae094","DOI":"10.1093\/oncolo\/oyae094"},{"key":"2","unstructured":"Centers for Disease Control and Prevention. (2024). Understanding the opioid overdose epidemic. U.S. Department of Health and Human Services. https:\/\/www.cdc.gov\/overdose-prevention\/about\/understanding-the-opioid-overdose-epidemic.html"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Chen, Y., Spillane, S., Shiels, M.S., Young, L., Quach, D., Berrington de Gonz\u00e1lez, A., & Freedman, N.D. (2021). Trends in opioid use among cancer patients in the United States: 2013\u20132018. JNCI Cancer Spectrum, 6(1), pkab095. https:\/\/doi.org\/10.1093\/jncics\/pkab095","DOI":"10.1093\/jncics\/pkab095"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Chwistek, M., Sherry, D., Kinczewski, L., Silveira, M.J., & Davis, M. (2023). Should buprenorphine be considered a first-line opioid for the treatment of moderate to severe cancer pain? Journal of Pain and Symptom Management, 66(5), e638\u2013e643. https:\/\/doi.org\/10.1016\/j.jpainsymman.2023.06.022","DOI":"10.1016\/j.jpainsymman.2023.06.022"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Fipps, D.C., Oesterle, T.S., & Kolla, B.P. (2024). Opioid maintenance therapy: A review of methadone, buprenorphine, and naltrexone treatments for opioid use disorder. Seminars in Neurology, 44(4), 441\u2013451. https:\/\/doi.org\/10.1055\/s-0044-1787571","DOI":"10.1055\/s-0044-1787571"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Fitzgerald Jones, K., Khodyakov, D., Arnold, R., Bulls, H., Dao, E., Kapo, J., . . . Merlin, J. (2022). Consensus-based guidance on opioid management in individuals with advanced cancer-related pain and opioid misuse or use disorder. JAMA Oncology, 8(8), 1107\u20131114. https:\/\/doi.org\/10.1001\/jamaoncol.2022.2191","DOI":"10.1001\/jamaoncol.2022.2191"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Heidbreder, C., Fudala, P.J., & Greenwald, M.K. (2023). History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder. Drug and Alcohol Dependence Reports, 6, 100133. https:\/\/doi.org\/10.1016\/j.dadr.2023.100133","DOI":"10.1016\/j.dadr.2023.100133"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Ho, J.J., Fitzgerald Jones, K., Sager, Z., Neale, K., Childers, J.W., Loggers, E., & Merlin, J.S. (2022). Barriers to buprenorphine prescribing for opioid use disorder in hospice and palliative care. Journal of Pain and Symptom Management, 64(2), 119\u2013127. https:\/\/doi.org\/10.1016\/j.jpainsymman.2022.05.004","DOI":"10.1016\/j.jpainsymman.2022.05.004"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Huang, T.-L., Huang, Y.-M., Hou, M.-M., Lu, C.-H., Chao, T.-Y., Chiu, T.-J., . . . Shen, W.-C. (2023). Safety and effectiveness of transdermal buprenorphine in cancer pain: An observational study in Taiwan (SOOTHE). Asia-Pacific Journal of Clinical Oncology, 19(2), e45\u2013e53. https:\/\/doi.org\/10.1111\/ajco.13772","DOI":"10.1111\/ajco.13772"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Merlin, J.S., Khodyakov, D., Arnold, R., Bulls, H.W., Dao, E., Kapo, J., . . . Liebschutz, J.M. (2021). Expert panel consensus on management of advanced cancer\u2013related pain in individuals with opioid use disorder. JAMA Network Open, 4(12), e2139968. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.39968","DOI":"10.1001\/jamanetworkopen.2021.39968"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Meyer, I., Chan, B., Cohen, E., Dube, E., Hu, R., Yeomans, M., . . . Tan, C.O. (2022). Use of a buprenorphine-based pain management protocol is associated with reduced opioid requirements and pain on swallowing in oral mucositis: A retrospective cohort study. Supportive Care in Cancer, 30(7), 6013\u20136020. https:\/\/doi.org\/10.1007\/s00520-022-07014-5","DOI":"10.1007\/s00520-022-07014-5"},{"key":"12","unstructured":"National Alliance of Advocates for Buprenorphine Treatment. (n.d.). Pharmacology of buprenorphine. https:\/\/www.naabt.org\/education\/pharmacoloy_of_buprenorphine.cfm"},{"key":"13","unstructured":"National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Adult cancer pain guidelines [v.3.2024]. https:\/\/www.nccn.org"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Neale, K.J., Weimer, M.B., Davis, M.P., Fitzgerald Jones, K., Kullgren, J.G., Kale, S.S., . . . Ho, J.J. (2023). Top ten tips palliative care clinicians should know about buprenorphine. Journal of Palliative Medicine, 26(1), 120\u2013130. https:\/\/doi.org\/10.1089\/jpm.2022.0399","DOI":"10.1089\/jpm.2022.0399"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Paice, J.A., Bohlke, K., Barton, D., Craig, D.S., El-Jawahri, A., Hershman, D.L., . . . Bruera, E. (2023). Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. Journal of Clinical Oncology, 41(4), 914\u2013930. https:\/\/doi.org\/10.1200\/JCO.22.02198","DOI":"10.1200\/JCO.22.02198"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Saloner, B., Andraka-Christou, B., Stein, B.D., & Gordon, A.J. (2023). Will the end of the X-waiver expand access to buprenorphine treatment? Achieving the full potential of the 2023 consolidated appropriations act. Substance Abuse, 44(3), 108\u2013111. https:\/\/doi.org\/10.1177\/08897077231186212","DOI":"10.1177\/08897077231186212"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Sandhu, S., & Calcaterra, S.L. (2024). How do I manage acute pain for patients prescribed buprenorphine for opioid use disorder? NEJM Evidence, 3(5), EVIDccon2300275. https:\/\/doi.org\/10.1056\/EVIDccon2300275","DOI":"10.1056\/EVIDccon2300275"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Shen, W.-C., Hou, M.-M., Huang, T.-L., Wang, C.-H., Huang, Y.-M., Chen, J.-S., & Chen, M.-L. (2023). Transdermal buprenorphine improves overall quality of life and symptom severity in cancer patients with pain. Journal of Clinical Nursing, 32(3\u20134), 539\u2013547. https:\/\/doi.org\/10.1111\/jocn.16303","DOI":"10.1111\/jocn.16303"},{"key":"19","unstructured":"Substance Abuse and Mental Health Services Administration. (2025). Buprenorphine telemedicine prescribing: Questions and answers. https:\/\/bit.ly\/4ba40r0"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Yennurajalingam, S., Arthur, J., Reddy, S., Edwards, T., Lu, Z., Rozman de Moraes, A., . . . Bruera, E. (2021). Frequency of and factors associated with nonmedical opioid use behavior among patients with cancer receiving opioids for cancer pain. JAMA Oncology, 7(3), 404\u2013411. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6789","DOI":"10.1001\/jamaoncol.2020.6789"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Yeung, A., G\u00e1lvez-Peralta, M., Apopa, J., Wyland, J., & Holbein, M. (2023). Patient\u2019s perceptions of buprenorphine use receiving treatment for cancer. Journal of Opioid Management, 19(4), 285\u2013289. https:\/\/doi.org\/10.5055\/jom.2023.0785","DOI":"10.5055\/jom.2023.0785"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/publications-research\/cjon\/29\/2\/buprenorphine-applications-oncology-and-palliative-care","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:47:45Z","timestamp":1763754465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/29\/2\/buprenorphine-applications-oncology-and-palliative-care"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,14]]}},"alternative-id":["82611"],"URL":"https:\/\/doi.org\/10.1188\/25.cjon.119-124","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2025,3,14]]}}}